Int J Clin Pharm
Other risk factors that may increase vulnerability include: Long duration of diabetes (typically more than 10 years) Poor glycaemic control prior to starting GLP-1 therapy (HbA1c significantly above target) Rapid reduction in HbA1c (a drop of more than 2 percentage points [22 mmol/mol] within 36 months) Concurrent hypertension , especially if poorly controlled Diabetic kidney disease (nephropathy), which often correlates with retinopathy severity Previous history of retinal treatment (laser photocoagulation or intravitreal injections) People with type 2 diabetes but no retinopathy appear to have minimal risk of retinopathy progression based on current evidence
Expert Rev Clin Pharmacol 16(11):10631072 Polyzos SA, Goulas A, Papaioannidou P (2023) Tirzepatide for diabetes and obesity: a new window to the treatment of non-alcoholic steatohepatitis
Conclusion GLP-1 medications have emerged as a promising tool for addressing obesity as a chronic condition, but theyre far from the quick fix often portrayed on social media
For example, the autophagy regulatory factor TP53INP2 can effectively promote the mitochondrial autophagy process, thereby reducing the accumulation of ROS within the cells and ultimately improving the related pathological phenotypes associated with sarcopenia [42]
Gastroenterology 162, 160216.e6
